2023 Joint Pre-ECTRIMS Course 10 October 2023 Milan, Italy

SCIENTIFIC PROGRAMME

A Continuing Medical Education Programme provided by



Fondazione Prada



Overview

Building on recent advancements in knowledge of pathogenic mechanisms and care of Multiple Sclerosis, this annual course aims at summarising all the main novelties of the year in the field of MS. Particularly, this edition of the meeting focuses on the pathogenetic mechanisms leading to neurodegeneration and clinical progression occurring inside the CNS, on the strategies to prevent MS worsening and promote repair, as well as on the digital tools suitable to measure disability progression. The controversies' session covers 'hot topics' for future debate including clinical trial design in progressive MS patients, the role of artificial intelligence in improving MS prediction, or the prognostic role of chronic active lesions quantification. The course presents the contribution of the world leading experts in each field of interest, creating for participants the opportunity to engage with inspiring researchers which are animating the current scientific scene in MS.

Learning objectives

- Describe the role of new immunological players, like microglia, in MS development
- Illustrate mechanisms of action and safety profile of new MS treatments for relapsing remitting and progressive MS
- Describe the role of chronic active lesions in sustaining progression
- Discuss how to apply artificial intelligence to improve disability prediction



Scientific Agenda

Welcome & Opening 10.00 G. Comi (Italy) and X. Montalban (Spain)

Session 1: Advancements in understanding Multiple Sclerosis

Chair: G Comi (Italy)

10.15	L1 - Is the Epstein Barr Virus the trigger and/or the driver of MS?
	G. Giovannoni (UK)

- 10.35 L2 Tissue-resident immune cells in the pathogenesis of MS H. Lassmann (Austria)
- 10.55 L3 MRI biomarkers of progression in MSC. Granziera (Switzerland)
- 11.15 Coffee break
- 11.45 L4 Discontinuing MS treatments in a stable disease: yes, or no?

 M. Tintorè (Spain)
- 12.05 L5 Current and future treatments in Relapsing MS X. Montalban (Spain)
- 12.25 L6 Current and future treatments in Progressive MSG. Comi (Italy)
- 12.45 L7 Enhancing myelin repair
 B. Stankoff (France)
- 13.05 Q&A
- 13.30 Lunch



Session 2: Burning questions in MS

Chair: X. Montalban (Spain)

14.30	D1 - PIRA: mechanistic or statistical construct?
	C. Tur (Spain) - F. Lublin (USA)

- 15.00 L8 Immunosenescence: friend or foe? V. Van Pesch (Belgium)
- 15.20 L9 Cognition in MS M. P. Amato (Italy)
- 15.40 L10 Digital medicine in MS L. Leocani (Italy)
- 16.00 L11 Use of Artificial intelligence in predicting prognosis in MS: values and limitsA.Eshaghi (UK)
- 16.20 Round Table: Observational real-world studies in MS: usefulness and criticism
 J. Hillert (Sweden), T. Kalinchik (Australia), A. Signori (Italy),
 M.Trojano (Italy)
- **16.50** Q&A
- **17.20** Wrap-up
- **17.30** End of the day



Scientific Organizers

Giancarlo Comi

Gallarate, Italy

MS Center, Neurorehabilitation Department Casa di Cura Igea Milan, Italy and Gallarate Hospital

Xavier Montalban

Neurology Department
Multiple Sclerosis Centre of
Catalonia (Cemcat)
and
Vall d'Hebron Barcelona Hospital
Campus
Barcelona, Spain

Accreditation -

An application for CME accreditation has been made to the European Accreditation Council for Continuing Medical Education (EACCME®).



Venue

Fondazione Prada

Largo Isarco, 2 Milan, Italy

Acknowledgement

This educational activity is made possible thanks to unrestricted educational grants by Roche and Sanofi.



Notes

Notes

Notes

Notes

Notes

